Is altimmune a good buy on the altimmune stock market?
The company was founded in 1997 and is headquartered in Gaithersburg, MD. Altimmune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
How does altimmune Inc's insider ownership look like?
In the past three months, Altimmune insiders have not sold or bought any company stock. Only 3.14% of the stock of Altimmune is held by insiders. 76.57% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Why is altaltimmune stock trading lower today?
Altimmune shares are trading lower after the company hosted a Key Opinion Leader call on its 12-week Phase 1 clinical trial of pemvidutide. Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.
Will altimmune (Alt) outperform or underperform the S&P 500?
MarketBeat's community ratings are surveys of what our community members think about Altimmune and other stocks. Vote “Outperform” if you believe ALT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALT will underperform the S&P 500 over the long term.
Should I buy Altimmune stock?
The financial health and growth prospects of ALT, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Is ALT a buy or sell?
BuyThe consensus among 4 Wall Street analysts covering (NASDAQ: ALT) stock is to Strong Buy ALT stock.
Will ALT stock go back up?
The 7 analysts offering 12-month price forecasts for Altimmune Inc have a median target of 25.00, with a high estimate of 30.00 and a low estimate of 12.00. The median estimate represents a +168.82% increase from the last price of 9.30.
Why is Altimmune dropping?
Altimmune Inc. ALT, +3.50% shares dropped in the extended session Tuesday after the biotech said it was discontinuing study of a COVID-19 nasal spray vaccine because it didn't work as well as anticipated.
Should I buy or sell Altimmune stock right now?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 6 buy ratings for the stoc...
What is Altimmune's stock price forecast for 2022?
6 brokerages have issued 1 year target prices for Altimmune's shares. Their forecasts range from $21.00 to $30.00. On average, they predict Altimmu...
How has Altimmune's stock performed in 2022?
Altimmune's stock was trading at $9.16 at the beginning of the year. Since then, ALT stock has decreased by 6.7% and is now trading at $8.55. View...
When is Altimmune's next earnings date?
Altimmune is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Altimmune .
How were Altimmune's earnings last quarter?
Altimmune, Inc. (NASDAQ:ALT) issued its earnings results on Thursday, May, 12th. The company reported ($0.44) earnings per share (EPS) for the quar...
When did Altimmune's stock split? How did Altimmune's stock split work?
Altimmune's stock reverse split on the morning of Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 201...
Who are Altimmune's key executives?
Altimmune's management team includes the following people: Dr. Vipin K. Garg Ph.D. , Pres, CEO & Director (Age 64, Pay $869.46k) Mr. Richard I....
Who are some of Altimmune's key competitors?
Some companies that are related to Altimmune include Taro Pharmaceutical Industries (TARO) , Sierra Oncology (SRRA) , Madrigal Pharmaceuticals (...
What other stocks do shareholders of Altimmune own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Altimmune investors own include Vaxart (VXRT) , Pfizer (P...
About Altimmune
Headlines
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases.
Altimmune (NASDAQ:ALT) Frequently Asked Questions
Are Intranasal Sprays The Next $36 Billion Trend in Vaccine Stocks? - Motley Fool
Analysts Estimate Altimmune, Inc. (ALT) to Report a Decline in Earnings: What to Look Out for
7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Altimmune stock. View analyst ratings for Altimmune or view top-rated stocks.
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Altimmune, Inc. (ALT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
It's been a bruising start to 2022 on Wall Street — and the tumble moved into correction territory Monday morning with the S&P 500 falling about 10% from a recent high. The markets have made their biggest declines since the early uncertainty of the Covid-19 pandemic.
Shareholders Will Likely Find Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Acceptable
Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Institutions Own Altimmune, Inc. (NASDAQ:ALT) Shares?
Shareholders may be wondering what CEO Vipin Garg plans to do to improve the less than great performance at Altimmune...
Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock?
If you want to know who really controls Altimmune, Inc. ( NASDAQ:ALT ), then you'll have to look at the makeup of its...
Share your Analysis on ALT
Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.
Company Profile
Join our contributor community and share your insights with millions of readers across the globe. Submit an article now